Related Experiment Videos
Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis
M Gironi1, R Furlan, M Rovaris
1Department of Neuroscience, San Raffaele Hospital, DIMER, Via Olgettina 48, 20132 Milan, Italy. mgironi@dongnocchi.it
Abstract:
The possible link between the opioid peptide beta endorphin and the heterogeneity of the clinical course of multiple sclerosis (MS) was investigated. Peripheral blood mononuclear cells (PBMC) concentrations of beta endorphin were measured in 50 patients in different phases of MS. Thirty nine patients also underwent post-contrast magnetic resonance imaging of the brain. Among MS forms, the highest beta endorphin concentrations were found in PBMC from patients with relapsing remitting MS and the lowest in patients with the progressive forms. Average beta endorphin concentrations were lower, although not significantly, in patients with than in those without magnetic resonance imaging enhanced lesions. These data suggest that beta endorphin may have a role in the downregulation of the inflammatory process.
Insights
Beta endorphin levels vary in multiple sclerosis (MS) patients. Higher concentrations were observed in relapsing-remitting MS, suggesting a role in reducing inflammation.
Area of Science:
- Neuroimmunology
- Endocrinology
Background:
- Multiple sclerosis (MS) exhibits diverse clinical presentations.
- The role of endogenous opioid peptides in MS pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the association between beta endorphin levels and the clinical heterogeneity of multiple sclerosis.
- To explore the potential immunomodulatory function of beta endorphin in MS.
Main Methods:
- Quantification of beta endorphin concentrations in peripheral blood mononuclear cells (PBMC) from 50 MS patients.
- Correlation analysis with clinical MS phenotypes (relapsing-remitting vs. progressive forms).
- Assessment of brain magnetic resonance imaging (MRI) findings, including contrast-enhanced lesions.
Main Results:
- PBMC beta endorphin levels were highest in relapsing-remitting MS and lowest in progressive MS forms.
- A non-significant trend towards lower beta endorphin concentrations was observed in patients with MRI-detected brain lesions.
- These findings indicate differential beta endorphin expression across MS disease courses.
Conclusions:
- Beta endorphin levels may serve as a biomarker for MS clinical course heterogeneity.
- The data support a potential role for beta endorphin in modulating inflammatory processes in multiple sclerosis.
- Further research is warranted to elucidate the therapeutic implications of beta endorphin in MS management.